Difference between revisions of "Interferon gamma-1b (Actimmune)"
Jump to navigation
Jump to search
m |
m |
||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1999-02-25: Initial FDA approval |
== Patient Drug Information== | == Patient Drug Information== | ||
Revision as of 15:32, 9 May 2023
General information
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it was used
History of changes in FDA indication
- 1999-02-25: Initial FDA approval
Patient Drug Information
Also known as
- Brand name: Actimmune